Schwartsmann G, Peters G J, Laurensse E, de Waal F C, Loonen A H, Leyva A, Pinedo H M
Department of Oncology, Free University Hospital, Amsterdam, The Netherlands.
Biochem Pharmacol. 1988 Sep 1;37(17):3257-66. doi: 10.1016/0006-2952(88)90636-3.
DUP 785 (NSC 368390; Brequinar sodium) is a new inhibitor of pyrimidine de novo biosynthesis with antitumor activity against several experimental tumors. DUP 785 inhibits the mitochondrial enzyme dihydroorotate dehydrogenase, blocking the conversion of dihydroorotate to orotate. We examined the influence of exposure time to DUP 785 on its growth-inhibitory effects in L1210 murine leukemia and WiDR human adenocarcinoma cells and the effects of pyrimidine (deoxy) nucleosides on reversal of growth-inhibition. The results were correlated with changes in intracellular pyrimidine nucleotide pools and cell cycle distribution. In L1210 cells, a continuous exposure to 25 microM DUP 785 up to 96 hr caused complete growth inhibition. A 2 hr exposure of cells to the drug did not affect growth. In WiDR cells, exposure to the drug for 1-24 hr, followed by cultivation in drug-free medium resulted in recovery of growth. However, cells exposed to the drug for 48 hr or longer were not able to resume growth when recultured in drug-free medium. Reversal studies were performed to know whether selective depletion of one of the pyrimidine (deoxy) nucleotides might be related to the growth-inhibitory effects of DUP 785. Neither thymidine, deoxycytidine alone, deoxycytidine plus tetrahydrouridine; nor cytidine plus tetrahydrouridine added after 24 hr were able to reverse cell growth inhibition induced by 25 microM DUP 785. However, uridine and cytidine alone reversed growth inhibition. UTP and CTP pools in L1210 cells decreased to about 30-40% of control levels after 4 hr of drug exposure, while dTTP and dCTP pools decreased to about 30% of control levels. There were no significant changes in purine nucleotide pools. In WiDR cells, UTP and CTP pools decreased rapidly after drug exposure and were substantially depleted after 24 hr. Reculture of cells in drug-free medium resulted in a significant recovery of UTP and CTP levels only for cells exposed to DUP 785 for 1-24 hr. For cells exposed to the drug for 48 and 72 hr recovery of nucleotide pools was minimal. In L1210 cells, a 12-hr exposure to the drug caused an accumulation of cells in the early S-phase. In WiDR cells, there was a clear accumulation of cells in the S-phase of the cell cycle after 24 hr drug exposure.(ABSTRACT TRUNCATED AT 400 WORDS)
DUP 785(NSC 368390;布喹那钠)是一种新型嘧啶从头生物合成抑制剂,对多种实验性肿瘤具有抗肿瘤活性。DUP 785抑制线粒体酶二氢乳清酸脱氢酶,阻断二氢乳清酸向乳清酸的转化。我们研究了DUP 785的暴露时间对其在L1210小鼠白血病细胞和WiDR人腺癌细胞中的生长抑制作用的影响,以及嘧啶(脱氧)核苷对生长抑制逆转的影响。结果与细胞内嘧啶核苷酸池的变化和细胞周期分布相关。在L1210细胞中,持续暴露于25 microM DUP 785长达96小时会导致完全生长抑制。细胞暴露于该药物2小时不影响生长。在WiDR细胞中,将细胞暴露于药物1 - 24小时,然后在无药物培养基中培养可恢复生长。然而,暴露于药物48小时或更长时间的细胞在无药物培养基中重新培养时无法恢复生长。进行了逆转研究以了解嘧啶(脱氧)核苷酸之一的选择性消耗是否可能与DUP 785的生长抑制作用有关。单独的胸苷、脱氧胞苷、脱氧胞苷加四氢尿苷;或24小时后添加的胞苷加四氢尿苷均不能逆转25 microM DUP 785诱导的细胞生长抑制。然而,单独的尿苷和胞苷可逆转生长抑制。药物暴露4小时后,L1210细胞中的UTP和CTP池降至对照水平的约30 - 40%,而dTTP和dCTP池降至对照水平的约30%。嘌呤核苷酸池无显著变化。在WiDR细胞中,药物暴露后UTP和CTP池迅速下降,24小时后大量耗尽。仅对于暴露于DUP 785 1 - 24小时的细胞,在无药物培养基中重新培养可导致UTP和CTP水平显著恢复。对于暴露于药物48小时和72小时的细胞,核苷酸池的恢复最小。在L1210细胞中,暴露于药物12小时会导致细胞在早期S期积累。在WiDR细胞中,药物暴露24小时后细胞周期的S期明显积累。(摘要截短于400字)